Junfang Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Junfang Qin has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Jing Yu
7 shared publications- Yue Wang
School of Medicine, Nankai University, Tianjin, China
7 shared publications Ning Li
School of Disaster and Emergency Medicine, Faculty of Medicine, Tianjin University
5 shared publicationsXiao Hu
Department of Immunology, School of Medicine, Nankai University
5 shared publicationsYu Xie
Houston Methodist Neal Cancer Center, Houston Methodist Research Institute Houston Texas USA
5 shared publicationsXianxian Duan
Department of Immunology, School of Medicine, Nankai University
4 shared publications
Latest Publications
- 27 July 2026
- Published by Elsevier in Experimental Cell Research
- Vol. 462 (1)
Neddylation cooperates with multiple phosphorylation to enhance FGFR1 stability and drive breast cancer progression
- 27 July 2026
- Published by Elsevier in Experimental Cell Research
- Vol. 462 (1)
Neddylation cooperates with multiple phosphorylation to enhance FGFR1 stability and drive breast cancer progression
- Open Access
Discovery of Capsazepine as a Novel MCL1 Inhibitor for Overcoming Tamoxifen Resistance in Breast Cancer Therapy
Tamoxifen resistance remains a significant clinical challenge in breast cancer. The anti‐apoptotic protein MCL1 is frequently overexpressed in tamoxifen‐resistant tumors and is associated with poor patient survival, underscoring its potential as a therapeutic target. To identify novel MCL1 inhibitors, we first confirmed MCL1 upregulation in tamoxifen‐resistant MCF7‐R cells and clinical specimens. Using high‐throughput virtual screening, molecular docking, and dynamics simulations, we identified capsazepine (CPZ) as a promising candidate. CPZ exhibited high binding affinity and formed stable interactions with key MCL1 residues, LEU267 and PHE270. Experimentally, CPZ significantly suppressed proliferation and induced mitochondrial‐dependent apoptosis in MCF7‐R cells. Importantly, CPZ synergized with tamoxifen to suppress colony formation and promote apoptosis, effectively reversing the resistant phenotype. Mechanistic studies using Drug Affinity Responsive Target Stability (DARTS) and functional assays confirmed that CPZ directly binds to and stabilizes MCL1. CPZ also demonstrated favorable drug‐like properties and a superior predicted toxicity profile compared to the established inhibitor UMI‐77. Our findings establish CPZ as a novel and effective MCL1 inhibitor that can help overcome tamoxifen resistance, offering a promising combined therapeutic strategy for endocrine‐resistant breast cancer.
Open AccessDiscovery of Capsazepine as a Novel MCL1 Inhibitor for Overcoming Tamoxifen Resistance in Breast Cancer Therapy
Tamoxifen resistance remains a significant clinical challenge in breast cancer. The anti‐apoptotic protein MCL1 is frequently overexpressed in tamoxifen‐resistant tumors and is associated with poor patient survival, underscoring its potential as a therapeutic target. To identify novel MCL1 inhibitors, we first confirmed MCL1 upregulation in tamoxifen‐resistant MCF7‐R cells and clinical specimens. Using high‐throughput virtual screening, molecular docking, and dynamics simulations, we identified capsazepine (CPZ) as a promising candidate. CPZ exhibited high binding affinity and formed stable interactions with key MCL1 residues, LEU267 and PHE270. Experimentally, CPZ significantly suppressed proliferation and induced mitochondrial‐dependent apoptosis in MCF7‐R cells. Importantly, CPZ synergized with tamoxifen to suppress colony formation and promote apoptosis, effectively reversing the resistant phenotype. Mechanistic studies using Drug Affinity Responsive Target Stability (DARTS) and functional assays confirmed that CPZ directly binds to and stabilizes MCL1. CPZ also demonstrated favorable drug‐like properties and a superior predicted toxicity profile compared to the established inhibitor UMI‐77. Our findings establish CPZ as a novel and effective MCL1 inhibitor that can help overcome tamoxifen resistance, offering a promising combined therapeutic strategy for endocrine‐resistant breast cancer.
- Open Access
- 15 April 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 57 (2) , 457-477
Synergistic Activation of LEPR and ADRB2 Induced by Leptin Enhances Reactive Oxygen Specie Generation in Triple-Negative Breast Cancer Cells
Purpose Leptin interacts not only with leptin receptor (LEPR) but also engages with other receptors. While the pro-oncogenic effects of the adrenergic receptor β2 (ADRB2) are well-established, the role of leptin in activating ADRB2 in triple-negative breast cancer (TNBC) remains unclear.Materials and Methods The pro-carcinogenic effects of LEPR were investigated using murine TNBC cell lines, 4T1 and EMT6, and a tumor-bearing mouse model. Expression levels of LEPR, NADPH oxidase 4 (NOX4), and ADRB2 in TNBC cells and tumor tissues were analyzed via western blot and quantitative real-time polymerase chain reaction. Changes in reactive oxygen species (ROS) levels were assessed using flow cytometry and MitoSox staining, while immunofluorescence double-staining confirmed the co-localization of LEPR and ADRB2.Results LEPR activation promoted NOX4-derived ROS and mitochondrial ROS production, facilitating TNBC cell proliferation and migration, effects which were mitigated by the LEPR inhibitor Allo-aca. Co-expression of LEPR and ADRB2 was observed on cell membranes, and bioinformatics data revealed a positive correlation between the two receptors. Leptin activated both LEPR and ADRB2, enhancing intracellular ROS generation and promoting tumor progression, which was effectively countered by a specific ADRB2 inhibitor ICI118551. In vivo, leptin injection accelerated tumor growth and lung metastases without affecting appetite, while treatments with Allo-aca or ICI118551 mitigated these effects.Conclusion This study demonstrates that leptin stimulates the growth and metastasis of TNBC through the activation of both LEPR and ADRB2, resulting in increased ROS production. These findings highlight LEPR and ADRB2 as potential biomarkers and therapeutic targets in TNBC.
- 15 April 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 57 (2) , 457-477
Open AccessSynergistic Activation of LEPR and ADRB2 Induced by Leptin Enhances Reactive Oxygen Specie Generation in Triple-Negative Breast Cancer Cells
Purpose Leptin interacts not only with leptin receptor (LEPR) but also engages with other receptors. While the pro-oncogenic effects of the adrenergic receptor β2 (ADRB2) are well-established, the role of leptin in activating ADRB2 in triple-negative breast cancer (TNBC) remains unclear.Materials and Methods The pro-carcinogenic effects of LEPR were investigated using murine TNBC cell lines, 4T1 and EMT6, and a tumor-bearing mouse model. Expression levels of LEPR, NADPH oxidase 4 (NOX4), and ADRB2 in TNBC cells and tumor tissues were analyzed via western blot and quantitative real-time polymerase chain reaction. Changes in reactive oxygen species (ROS) levels were assessed using flow cytometry and MitoSox staining, while immunofluorescence double-staining confirmed the co-localization of LEPR and ADRB2.Results LEPR activation promoted NOX4-derived ROS and mitochondrial ROS production, facilitating TNBC cell proliferation and migration, effects which were mitigated by the LEPR inhibitor Allo-aca. Co-expression of LEPR and ADRB2 was observed on cell membranes, and bioinformatics data revealed a positive correlation between the two receptors. Leptin activated both LEPR and ADRB2, enhancing intracellular ROS generation and promoting tumor progression, which was effectively countered by a specific ADRB2 inhibitor ICI118551. In vivo, leptin injection accelerated tumor growth and lung metastases without affecting appetite, while treatments with Allo-aca or ICI118551 mitigated these effects.Conclusion This study demonstrates that leptin stimulates the growth and metastasis of TNBC through the activation of both LEPR and ADRB2, resulting in increased ROS production. These findings highlight LEPR and ADRB2 as potential biomarkers and therapeutic targets in TNBC.
- 1 July 2024
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 35 (9) , 830-843
Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
There is a substantial unmet need for effective treatment strategies in triple-negative breast cancer (TNBC). Recently, renewed attention has been directed towards targeting glutamine (Gln) metabolism to enhance the efficacy of cancer treatment. Nonetheless, a comprehensive exploration into the mechanistic implications of targeting Gln metabolism in TNBC is lacking. In this study, our objective was to probe the sensitivity of TNBC to alterations in Gln metabolism, using representative TNBC cell lines: MDA-MB-231, MDA-MB-468, and 4T1. Through an integration of bioinformatics, in-vitro, and in-vivo investigations, we demonstrated that sulfasalazine (SAS), like erastin (a known xCT inhibitor), effectively suppressed the expression and transport function of xCT, resulting in a depletion of glutathione levels in MDA-MB-231 and MDA-MB-468 cells. Furthermore, both xCT knockdown and SAS treatment demonstrated the promotion of cellular autophagy. We unveiled a positive correlation between xCT and the autophagy-related molecule p62, their co-expression indicating poor survival outcomes in breast cancer patients. In addition, our research revealed the influence of SAS and xCT on the expression of proteins regulating cell cycle and proliferation. Treatment with SAS or xCT knockdown led to the inhibition of MYC, CDK1, and CD44 expression. Significantly, the combined administration of SAS and rapamycin exhibited a synergistic inhibitory effect on the growth of transplanted breast tumor in mouse models constructed from murine-derived 4T1 cells. Taken together, our findings suggested the potential and clinical relevance of the SAS and rapamycin combination in the treatment of TNBC.
- 1 July 2024
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 35 (9) , 830-843
Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
There is a substantial unmet need for effective treatment strategies in triple-negative breast cancer (TNBC). Recently, renewed attention has been directed towards targeting glutamine (Gln) metabolism to enhance the efficacy of cancer treatment. Nonetheless, a comprehensive exploration into the mechanistic implications of targeting Gln metabolism in TNBC is lacking. In this study, our objective was to probe the sensitivity of TNBC to alterations in Gln metabolism, using representative TNBC cell lines: MDA-MB-231, MDA-MB-468, and 4T1. Through an integration of bioinformatics, in-vitro, and in-vivo investigations, we demonstrated that sulfasalazine (SAS), like erastin (a known xCT inhibitor), effectively suppressed the expression and transport function of xCT, resulting in a depletion of glutathione levels in MDA-MB-231 and MDA-MB-468 cells. Furthermore, both xCT knockdown and SAS treatment demonstrated the promotion of cellular autophagy. We unveiled a positive correlation between xCT and the autophagy-related molecule p62, their co-expression indicating poor survival outcomes in breast cancer patients. In addition, our research revealed the influence of SAS and xCT on the expression of proteins regulating cell cycle and proliferation. Treatment with SAS or xCT knockdown led to the inhibition of MYC, CDK1, and CD44 expression. Significantly, the combined administration of SAS and rapamycin exhibited a synergistic inhibitory effect on the growth of transplanted breast tumor in mouse models constructed from murine-derived 4T1 cells. Taken together, our findings suggested the potential and clinical relevance of the SAS and rapamycin combination in the treatment of TNBC.
- 31 May 2024
- Published by Elsevier in Life Sciences
- Vol. 350, 122763
Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation
- 31 May 2024
- Published by Elsevier in Life Sciences
- Vol. 350, 122763
Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation
- Open Access
- 5 May 2024
- Published by Wiley in Cancer Science
- Vol. 115 (7) , 2318-2332
LINC00173 silence and estrone supply suppress ER+ breast cancer by estrogen receptor α degradation and LITAF activation
Persistent activation of estrogen receptor alpha (ER alpha)-mediated estrogen signaling plays a pivotal role in driving the progression of estrogen receptor positive (ER+) breast cancer (BC). In the current study, LINC00173, a long non-coding RNA, was found to bind both ER alpha and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF alpha) factor (LITAF), then cooperatively to inhibit ER alpha protein degradation by impeding the nuclear export of ER alpha. Concurrently, LITAF was found to attenuate TNF alpha transcription after binding to LINC00173, and this attenuating transcriptional effect was quite significant under lipopolysaccharide stimulation. Distinct functional disparities between estrogen subtypes emerge, with estradiol synergistically promoting ER+ BC cell growth with LINC00173, while estrone (E1) facilitated LITAF-transcriptional activation. In terms of therapeutic significance, silencing LINC00173 alongside moderate addition of E1 heightened TNF alpha and induced apoptosis, effectively inhibiting ER+ BC progression.
- 5 May 2024
- Published by Wiley in Cancer Science
- Vol. 115 (7) , 2318-2332
Open AccessLINC00173 silence and estrone supply suppress ER+ breast cancer by estrogen receptor α degradation and LITAF activation
Persistent activation of estrogen receptor alpha (ER alpha)-mediated estrogen signaling plays a pivotal role in driving the progression of estrogen receptor positive (ER+) breast cancer (BC). In the current study, LINC00173, a long non-coding RNA, was found to bind both ER alpha and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF alpha) factor (LITAF), then cooperatively to inhibit ER alpha protein degradation by impeding the nuclear export of ER alpha. Concurrently, LITAF was found to attenuate TNF alpha transcription after binding to LINC00173, and this attenuating transcriptional effect was quite significant under lipopolysaccharide stimulation. Distinct functional disparities between estrogen subtypes emerge, with estradiol synergistically promoting ER+ BC cell growth with LINC00173, while estrone (E1) facilitated LITAF-transcriptional activation. In terms of therapeutic significance, silencing LINC00173 alongside moderate addition of E1 heightened TNF alpha and induced apoptosis, effectively inhibiting ER+ BC progression.
- 3 February 2022
- Published by Elsevier in Life Sciences
- Vol. 294, 120370
Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway
- 3 February 2022
- Published by Elsevier in Life Sciences
- Vol. 294, 120370
Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway
- 28 January 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 412 (2) , 113044
ZEB1 induces ROS generation through directly promoting MCT4 transcription to facilitate breast cancer
- 28 January 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 412 (2) , 113044
ZEB1 induces ROS generation through directly promoting MCT4 transcription to facilitate breast cancer
- 4 August 2021
- Published by Wiley in Molecular Carcinogenesis
- Vol. 60 (10) , 702-714
Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells
Monocarboxylate transporter 4 (MCT4) is highly expressed in various types of solid neoplasms including breast cancer (BC); however, the pro‐tumor functions underlying its increased expression have not been explained. Here, we examined the roles of posttranslational modifications to MCT4 in BC, particularly SUMOylation. Our findings revealed that SUMOylation of MCT4 inhibited its degradation and stabilized MCT4 protein levels, while ubiquitination facilitated MCT4 degradation. The E3 ubiquitin ligases β‐TRCP and FBW7 interacted with MCT4 at the DSG‐box and TPETS sequences, respectively, and Lys448 (K448) of MCT4 could be modified by SUMO chains. Our key finding was that K448 was crucial for MCT4 SUMOylation. Moreover, mutations of K448 abolished MCT4 expression, delaying the growth of BC. This study suggested that SUMOylation of K448 increased MCT4 levels, and mutations of K448 in MCT4 could have therapeutic significance in BC.
- 4 August 2021
- Published by Wiley in Molecular Carcinogenesis
- Vol. 60 (10) , 702-714
Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells
Monocarboxylate transporter 4 (MCT4) is highly expressed in various types of solid neoplasms including breast cancer (BC); however, the pro‐tumor functions underlying its increased expression have not been explained. Here, we examined the roles of posttranslational modifications to MCT4 in BC, particularly SUMOylation. Our findings revealed that SUMOylation of MCT4 inhibited its degradation and stabilized MCT4 protein levels, while ubiquitination facilitated MCT4 degradation. The E3 ubiquitin ligases β‐TRCP and FBW7 interacted with MCT4 at the DSG‐box and TPETS sequences, respectively, and Lys448 (K448) of MCT4 could be modified by SUMO chains. Our key finding was that K448 was crucial for MCT4 SUMOylation. Moreover, mutations of K448 abolished MCT4 expression, delaying the growth of BC. This study suggested that SUMOylation of K448 increased MCT4 levels, and mutations of K448 in MCT4 could have therapeutic significance in BC.